Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition
Olga K. Mirzoeva, W. Michael Korn(Itasca Community College), Richard M. Neve(Lawrence Berkeley National Laboratory), Zachary A. Knight(Howard Hughes Medical Institute), Philippe Gascard(University of California, San Francisco), Joe W. Gray(University of Newcastle Australia), Andrew J. Wyrobek(Lawrence Berkeley National Laboratory), Heidi S. Feiler(Oregon Health & Science University), Paul T. Spellman(Oregon Health & Science University), Debopriya Das(Lawrence Berkeley National Laboratory), Rina Gendelman, Bahram Parvin(University of Nevada, Reno), Doris R. Siwak(The University of Texas MD Anderson Cancer Center), Mina J. Bissell(Lawrence Berkeley National Laboratory), Kevan M. Shokat(Howard Hughes Medical Institute), Sanchita Bhattacharya(University of California, San Francisco), Frank McCormick(Frederick National Laboratory for Cancer Research), Laura M. Heiser(Oregon Health & Science University), Zhi Hu(Oregon Health & Science University), Wen-Lin Kuo(Lawrence Berkeley National Laboratory), Nora Bayani(Lawrence Berkeley National Laboratory), Yinghui Guan(Harbin Medical University), Nicholas J. Wang(Oregon Health & Science University), Gordon B. Mills(The University of Texas MD Anderson Cancer Center)
Cited by 390
Related Papers
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
|Nature|2013|2.5k
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k